Before the COVID-19 lockdowns and social distancing measures put face-to-face business routines and conference attendance on hold, Carlo Rivis was a regular on the investor meeting circuit, building up awareness of the mathematical modeling technologies that he says will one day be a viable alternative to traditional clinical trials.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?